You may not immediately recognize the name Abbott Laboratories (NYSE: ABT), but you've probably come into close contact with one of the company's many products -- from a coronavirus test to Ensure ...

Abbott's dividend track record demonstrates consistency. The company has increased its dividend for 13 consecutive years, with the annual payout growing from $1.04 in 2016 to $2.36 in 2025 - a 127% ...

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the ...

Abbott Laboratories (NYSE:ABT) produces a wide range of healthcare products and medical devices, with its business divided into four main areas: established pharmaceuticals, diagnostics, nutrition, ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the ...

Abbott Laboratories' business, if not exciting, is resilient and consistent. The company is a leader in multiple markets and has attractive growth avenues. The medical device leader boasts a strong ...

There are few names in healthcare that combine durability, innovation, and income quite like Abbott Laboratories (ABT). Yet ,even the strongest operators hit periods where sentiment softens and ...

Dividend King Abbott Laboratories' (ABT) post-earnings sell-off enhances the investment thesis for long-term investors even more in my opinion. The dividend yield, despite not being overly attractive ...

Abbott Labs is trading sharply lower following its Q4 earnings report, mirroring the negative reaction seen in peer Johnson & Johnson (JNJ) after its Q4 results. Abbott delivered in-line EPS, ...